US · BIOA
BioAge Labs, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Emeryville, CA 94804
- Website
- bioagelabs.com
Price · as of 2024-12-31
$16.79
Market cap 798.49M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $4.55 |
AI valuation
Our deep-learning model estimates BioAge Labs, Inc.'s (BIOA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $16.79
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BIOA | BioAge Labs, Inc. | $16.79 | 798.49M | — | — | — | — | -0.69 | 0.15 | — | 4.33 | — | 0.15 | 0.00% | — | — | -94.98% | 95.18% | -37.02% | 0.03 | -33.04 | 12.86 | 12.76 | 5.04 | -2246.00% | — | 3826.00% | -106.31% | -1.85 | 63.16% | 0.00% | 0.00% | 772.94% | 3.80 | 5.72 | — | 0.23 |
| ACB | Aurora Cannabis Inc. | $3.84 | 217.76M | +498% | -40% | +80% | -82% | 27.82 | 0.78 | 1.28 | 6.97 | — | 0.92 | 54.65% | 1.44% | 0.46% | 2.80% | 0.80% | 1.87% | 0.18 | 0.59 | 4.31 | 2.06 | -1.56 | -10223.00% | 2701.00% | -9666.00% | -0.65% | 0.15 | -0.59% | 0.00% | 0.00% | 0.12% | 72.30 | -125.35 | 1.04 | -8.43 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| AVIR | Atea Pharmaceuticals, Inc… | $4.68 | 365.63M | — | — | — | — | -1.50 | 0.57 | — | 1.53 | -6.59 | 0.57 | 0.00% | — | — | -33.88% | 1111.34% | -31.78% | 0.00 | — | 24.85 | 24.44 | 0.48 | 2270.00% | — | 5867.00% | -53.78% | -7.28 | 780.43% | 0.00% | 0.00% | 0.00% | 1.04 | 1.48 | — | 4.54 |
| CABA | Cabaletta Bio, Inc. | $3.32 | 319.6M | — | — | — | — | -0.79 | 0.60 | — | 0.51 | -1.89 | 0.60 | 0.00% | — | — | -59.64% | -6352.34% | -52.82% | 0.10 | -167.30 | 6.15 | 6.05 | 1.35 | 4182.00% | — | 6674.00% | -98.71% | -3.26 | -4590.51% | 0.00% | 0.00% | 0.00% | 0.45 | 0.63 | — | -2.29 |
| CGC | Canopy Growth Corporation | $1.12 | 576.26M | +725% | -39% | — | +204% | -0.42 | 0.52 | 0.95 | -0.99 | — | 0.72 | 29.56% | -43.55% | -222.35% | -122.35% | -14.04% | -54.48% | 0.72 | -1.57 | 3.12 | 1.95 | -0.49 | -3709.00% | -947.00% | -3809.00% | -69.30% | -1.76 | -21.21% | 0.00% | 0.00% | 102.99% | -4.03 | -2.67 | 1.76 | -16.18 |
| EDIT | Editas Medicine, Inc. | $2.20 | 214.76M | +883% | +13% | — | +6,172% | -0.60 | 1.05 | 4.38 | 0.40 | -1.40 | 1.05 | 100.00% | -777.22% | -733.72% | -98.10% | 1925.86% | -56.40% | 0.26 | — | 3.75 | 3.71 | 0.41 | 4257.00% | -5864.00% | 6005.00% | -154.71% | -2.72 | 1680.16% | 0.00% | 0.00% | 15.11% | 0.37 | 0.43 | -2.89 | -7.20 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| LFCR | Lifecore Biomedical, Inc. | $7.20 | 269.76M | +1,115% | -61% | — | — | -6.29 | 182.17 | 1.89 | -41.53 | — | -14.53 | 31.27% | -13.38% | -30.04% | -612.08% | -13.25% | -15.70% | 97.92 | -0.79 | 2.84 | 1.72 | -13.91 | -48485.00% | 47.00% | -2490.00% | -5.60% | -0.01 | -10.46% | 0.00% | 0.00% | 1.05% | -21.22 | -26.87 | 2.84 | -0.01 |
| OMI | Owens & Minor, Inc. | $2.68 | 207.07M | +942% | +49% | — | — | -2.12 | 1.36 | 0.07 | 48.40 | -0.28 | -0.72 | 20.74% | -1.94% | -3.39% | -48.70% | -7.35% | -7.44% | 3.79 | -1.44 | 1.08 | 0.39 | 35.40 | 76000.00% | 355.00% | -11251.00% | -8.69% | 0.09 | -2.36% | 0.00% | 0.00% | 0.00% | -13.75 | -42.87 | 0.27 | 2.30 |
| TKNO | Alpha Teknova, Inc. | $2.58 | 138.11M | +974% | -63% | — | — | -7.38 | 1.85 | 3.14 | -13.45 | — | 2.24 | 33.17% | -41.90% | -42.59% | -22.83% | -21.20% | -15.52% | 0.22 | -23.91 | 4.58 | 1.40 | -0.91 | -4386.00% | 735.00% | -3170.00% | -7.25% | -1.07 | -11.53% | 0.00% | 0.00% | 13.58% | -8.04 | -14.79 | 3.37 | 0.52 |
About BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
- CEO
- Kristen Fortney
- Employees
- 62
- Beta
- 1.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $16.79) − 1 = — (DCF, example).